logo
  

Sherwin-Williams Boosts FY23 Outlook - Update

While reporting financial results for the second quarter on Tuesday, paint and coating manufacturer Sherwin-Williams Co. (SHW) raised its earnings, adjusted earnings and sales growth guidance for the full-year 2023. The company also provided sales growth guidance for the third quarter.

For fiscal 2023, the company now projects earnings in a range of $8.46 to $8.86 per share and adjusted earnings in a range of $9.30 to $9.70 per share on consolidated net sales growth in low-single digit percentage.

Previously, the company expected earnings in a range of $6.79 to $7.59 per share and adjusted earnings in a range of $7.95 to $8.65 per share on consolidated net sales between down in mid-single digit percentage and flat.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $8.82 per share on net sales decline of 0.6 percent to $22.02 billion for the year. Analysts' estimates typically exclude special items.

For the third quarter, the company anticipates consolidated net sales to be up or down in low-single digits from last year, while analysts are looking for a decline of 5.6 percent to $5.71 billion.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Burger King Co., owned by Restaurant Brands International Inc., is planning to launch $5 value meal to boost demand among Americans, who are cutting back on dining out, reports said. The fast-food hamburger chain's offer is said to include a choice of one of three sandwiches, with nuggets, fries, and a drink. The news comes after rival chain McDonald's reportedly announced a plan to introduce... Microsoft has launched a new category of Windows PCs designed for Artificial Intelligence (AI) that are slated to be the fastest and most intelligent Windows PCs ever built. The Copilot+ PCs come with built-in AI hardware and will support AI features across the operating system. Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT